Although a numerically greater reduction in HbA1C with aspart did not reach statistical significance, more patients treated with aspart (59.7%) achieved target HbA1C levels compared with patients treated with lispro (43.8%; P < .04).
← all excerpts
Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.
1
0.0400
0.0400